Latest Content

Researchers find that epigenetic changes from the famine caused CV and mental health effects for 3 to 4 generations on both sides of the Atlantic.

Rising global temperatures are silently driving a sedentary crisis, and the world’s most vulnerable populations are paying the steepest price.

Severe COVID-19 was rare in patients with multiple sclerosis even when vaccine responses were impaired.

Secukinumab becomes the only IL-17A inhibitor approved for this population and the first new mechanism in the indication in nearly a decade.

Phase 3 data show lebrikizumab improves skin clearance and itch in children with moderate to severe atopic dermatitis, supporting potential pediatric label expansion.

Vutrisiran kept a favorable safety profile in patients with transthyretin amyloidosis treated for up to 58 months, with AE rates comparable to placebo and no new safety concerns.

Legislation that passed the Senate will introduce reform in how pharmacy benefit managers are addressed by CMS starting in 2028.

Dr Wilfong's commentary will appear in the April issue of Evidence-Based Oncology.

Galleri trial data show liquid biopsy multicancer early detection tests may cut stage IV diagnoses, despite the missed primary end point.